DicIofenac is a non-steroidal anti-inflammatory drug available in an ophthalmic preparation. We present a prospective randomised double-masked placebo-con trolled trial involving 40 patients that assessed the effectiveness of topical dicIofenac in relieving pain from traumatic corneal abrasions. Statistical analysis of visual analogue and categorical pain scores revealed a significant reduction in pain experienced by subjects in the dicIofenac group (p<0.02).
Traumatic corneal epithelial abrasion is a common reason for attendance at accident and emergency and eye departments. Patients with corneal epithelial injury experience significant ocular pain especially in the first 24--48 hours, and often until corneal re epithelialisation. 1 Despite the use of cycloplegics, patching and oral painkillers the pain is inadequately controlled in many patients. Topical anaesthetics are known to be toxic to the corneal epithelium and are therefore not normally used for analgesia. Corneal epithelial wounds heal by a process of cell migration and proliferation and the majority of these abrasions heal within 1-4 days ? , 3 Diclofenac is a potent non-steroidal anti-inflam matory drug (NSAID) used to relieve the pain and inflammation in conditions such as rheumatoid arthritis, degenerative joint disease and other inflam matory conditions. 4 An ophthalmic preparation of dic10fenac sodium 0.1 % solution is available for the treatment of post-operative inflammation.
We present the results of a prospective rando mised double-masked placebo-controlled compara-tive trial to determine the effectiveness of topical diclofenac in reducing pain caused by traumatic corneal abrasions.
PATIENTS AND METHODS
This study was a prospective double-masked com parison of diclofenac and placebo involving a total of 20 patients in each group and had the prior approval of the hospital ethics committee. Patients were recruited from the eye casualty department at Newcastle General Hospital. Those included in the study presented within 24 hours with a unilateral corneal abrasion and no other injury. Patients with previous corneal pathology, including dystrophies and recurrent erosion syndrome, diabetes, and those under 18 years of age or with known hypersensitivity to either NSAIDs or chloramphenicol were excluded. Written informed consent was obtained from all patients by the examining doctor.
Patients' pain was assessed in three ways (Fig. 1) . Firstly, a visual analogue scale was used in which the patient placed an 'x' on a horizontal line measuring 10 cm in length showing a continuum from 'no pain' to 'worst pain ever'. Secondly, a categorical pain scale was c o mpleted, allowing the patient to describe the eye pain as none, mild discomfort not requiring painkillers, moderate pain requiring painkillers or severe disabling pain. Thirdly, pain was further sub categorised into foreign body sensation, light sensi tivity and headache-like deep pain within the eye, and the patient was requested to describe the above categories as none, mild, moderate or severe.
Patients were randomly assigned to one of the two treatment groups: either diclofenac 0.1 % or placebo (normal saline). The drops were dispensed in unmarked containers, to be used 4 times per day in the affected eye, in addition to the chloramphenicol ointment routinely used in this condition. Neither eye pads nor cycloplegics were used in order to
Visual analogue pain scale
Please place an "X" on the line below to indicate the amount of pain, if any, that you have felt over the last 24 hours.
Mild
Moderate
The amount of pain in your affected eye over the last 24 hours: simplify the treatment regime, and patients were advised to take adequate oral analgesia as required.
No specific instructions were given regarding the type or amount of oral analgesics to be taken, since the design of the categorical pain scale grouped all patients who took oral analgesics into the same category independent of the amount or type (Fig. 2) . Doctors involved in the patient assessments were masked as to the study drug codes. Provision was made for 'code breaking' in the event of adverse effects.
The patients were reviewed daily until complete corneal re-epithelialisation occurred, and at each visit a patient was asked to quantify his or her pain over the preceding 24 hours on the same scales. The size of the abrasion was also documented daily by measuring the greatest dimensions with the slit beam, in order to ensure that healing was occurring. A full slit lamp examination was also performed.
With regard to the statistical analysis of the data in the two groups, it was felt appropriate to use a distribution-free method, so the Wilcoxon rank sum test for two samples was employed. As differences between the two groups were expected in one direction only, single-tailed significance values are shown in the results. Data from day 0 to day 2 were compared.
RESULTS
All patients completed the study as planned and no unmasking of patients occurred during the trial. All patients in both groups had suffered relatively minor ocular trauma from accidental scratches with fingers, plants and stationery items. There were no adverse drug effects observed and all corneal abrasions were healed by 96 hours. No attempt was made to measure the area of the abrasions as this would have been impractical and inaccurate. Therefore, it was not possible to compare abrasion size with severity of pain.
The categorical pain scale data for day 0 (time of presentation), day 1 and day 2 are shown in Fig. 2 . On day 0 there was no statistically significant difference in the distribution of scores between the placebo and diclofenac groups. On day 1 the diclofenac score distribution was statistically smaller than that of the placebo (Wilcoxon rank sums Tl = 338, T2 = 482, Nl = N2 = 20, P = 0.025). By day 2 the difference had increased further but on reduced data sets (Wilcoxon rank sums Tl = 149.5, T2 = 40.5, Nl = 9, N2 = 10, p<O.OOl).
The visual analogue scale data presented substan tially the same picture, albeit with higher significance on day 1 (Wilcoxon rank sums Tl = 355, T2 = 506, Nl = N2 = 20, p<0.002). Fig. 3a -c represents foreign body sensation, light sensitivity (photophobia) and headache-like pain during the first 48 hours. The placebo group experienced moderate or severe levels of discomfort in the three categories more frequently than did the diclofenac group. 
DISCUSSION
evidence exists in the medical literature that dicloTraditional treatment of corneal abrasions includes antibiotic ointment, cycloplegics and oral analgesics. Eye pads are advocated by certain clinicians but at least one study has shown delayed healing with the use of pads and no improvement in patient comfort. 5 Topical anaesthetic agents are avoided as these are believed to delay epithelial healing. The pain after corneal epithelial loss can be very severe and many patients are unable to return to work despite the above measures. 1 A number of mechanisms may produce pain following traumatic corneal abrasions. Mechanical disruption of the epithelium can result in breakdown of cell membranes and the release of chemical factors such as prostaglandins, substance P and histamine. These chemical mediators have been shown to produce pain. 6 Rapid re-epithelialisation after traumatic corneal abrasions is desirable to reduce risk of infection and eliminate pain. No fenac interferes with the rate of corneal epithelial healing. Indeed, diclofenac administered 4 times daily has been shown to have no effect on corneal wound healing or epithelial migration rate in animal models ? There were no cases in our study of abrasions which failed to heal quickly in either group. A known cause of persistent epithelial defects is preservative toxicity. 8 The preparation of diclo fenac used in this study was preservative-free single dose units.
Recently, the pain following corneal abrasions following excimer laser photorefractive keratectomy has been successfully treated with diclofenac eye drops. 1 Diclofenac is a potent non-steroidal anti inflammatory drug (NSAID). The mechanism of action of N S AIDs is the inhibition of the enzyme cyclo-oxygenase. 4 Cyclo-oxygenase inhibitors pro duce some of their effect by inhibiting the production of prostaglandins. Prostaglandin E 2 is generally thought to be responsible for inflammation and pain. Prostaglandin-synthesising capacity exists in the corneal epithelium and stroma and increases rapidly after injury. 9 It is likely that the analgesic properties of diclofenac are produced through a decrease in the production of prostaglandins lO and may also be related to increases in beta-endorphin production. ll Corneal nerve conduction is also depressed by topical diclofenac. 1 2 Systematic assays of patient discomfort are widely used in the field of clinical pharmacology regarding pain and pain relief 13 , 14 and it is accepted that the analogue scale provides a very sensitive 'between treatment' comparison when measuring ocular discomfort. IS In this study, the visual analogue scale and categorical scales both demonstrated that diclofenac is significantly more effective than placebo at reducing discomfort following traumatic corneal abrasions. Topical diclofenac also reduced the need for oral analgesics, as demonstrated by the statistical analysis of the categorical pain scale data and the degree of pain and light sensitivity.
The treatment regimen of topical diclofenac sodium (0.1 %) and antibiotic ointment 4 times daily as outlined in this article appears to provide a superior alternative to the traditional treatment of corneal abrasions.
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